This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
BCMA-targeting chimeric antigen receptor T cells increasingly look like a potent option for multiple myeloma. Across several candidates spotlighted during the 2019 American Society of Hematology Annual Meeting, high response rates were seen in patients whose disease was refractory to multiple standard therapies.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
February 2020
Volume 10, Issue 2
Volume 10, Issue 2
Multiple Myeloma: The CAR T-cell Therapy Landscape
Jump to section
Advertisement